Is SRPT a bull’s dream? Oppenheimer’s Hartaj Singh believes with commercial and clinical momentum into the new year, and no real DMD rivals for 3 to 5 years, the drug maker is a good bet.
Cantor: CELG pipeline needs commercial juice; Cowen: Sarepta soars on strong Exondys 51 orphan launch.
